Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2
Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.
Too Old to Operate9h
Assessing Myocardial Perfusion and Prognosis After PCI in STEMI
The following is a summary of "Low-dose dobutamine stress myocardial contrast echocardiography for evaluating myocardial ...
Scientific Research Publishing11h
Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One Year ()
Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...
The Lancet20h
Mechanical circulatory support for cardiogenic shock
The recent study by Holger Thiele and colleagues1 offers an extensive meta-analysis on the use of mechanical circulatory support (MCS) in acute myocardial infarction-related cardiogenic shock (AMICS).
KSNF Joplin on MSN23h
Medical Focus: What’s a STEMI and how are they treated at Freeman Health System?
Our American Heart Month coverage wraps up tonight with a look at some of the most deadly cardiovascular issues and how ...